Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule.
8 Dec, 2021 | 10:12h | UTCInvited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases